modum.io has announced the launch of its ICO campaign, starting September 1, 2017, as it targets $8.1 trillion per year global logistics market.
September 1, 2017, Zurich, Switzerland – modum.io has announced the public crowdsale of its MOD token starting September 1, 2017, following a very successful private pre-sale. The platform implementing blockchain and Internet of Things technology within the pharma supply chain witnesses token sales worth around $1.25 million within 24 hours in its recently concluded private pre-sale.
modum.io has allocated 20.1 million of the total 30 million MOD tokens for crowdsale. With 2.1 million already sold in the invite-only pre-sale, the remaining 18.1 million will be sold in three tiers during the upcoming ICO. The platform will offer the first 6 million tokens at a 30% discount. The second set of tokens will be issued with a 15% discount and the last 6 million will be sold at full price.
Additionally, modum.io will set aside 9.9 million tokens in a smart contract for use in the bug bounty program as well as profit sharing rights for the next three years.
modum.io has developed sensors that record the environmental conditions a package experiences en route to its destination. Senders will be able to pre-program parameters so that they can be notified if a change in the environment that may affect the product has occurred.
Use of the blockchain for audit-ability allows this sensor to fulfill regulatory requirements, and the passive nature of the devices themselves could bring about industry wide savings of $3.6 billion per annum.
Modum.io’s CEO, Malik El Bay, explains:
“We have a solid product with several successful pilot tests completed, a working hardware prototype, a strong team of developers, and a handpicked team of advisors. We are running this token sale to fundraise for the future development of modum.io and will give our cryptocurrency backers the same rights that institutionalized investors have.”The token will be built upon the Ethereum blockchain, with 1 MOD being worth $1.00. Participants in the initial token sale can purchase the tokens against payment made in Bitcoin, Ethereum or IOTA, owing to the platform’s strategic partnership with IOTA to create an infrastructure allowing transactions without cost-prohibitive fees as needed.
According to El Bay,
“To execute our vision, we need a technology for our sensor devices that allows the transfer of value without charging tremendous transaction fees. IOTA’s infrastructure will be very valuable to us and are working towards a proof-of-concept for our next industry tests. We plan to publish the results by fall 2017.”
While Ethereum is chosen as the blockchain on which smart contracts are created, the modum.io platform itself will be blockchain agnostic, and the team behind the project is already looking for ways to integrate other smart contract-enabled blockchains.
Token holders will not only enjoy profit dividends but also voting rights, proportional to the number of tokens they hold.
Located in Zurich, between the “Crypto Valley” in Zug and Basel, a hub for major pharma players, Modum is well positioned to bring their system to market. Modum works from Technopark, a well-established centre for tech start-ups and innovation in Switzerland. The company benefits from strategic partnerships with the University of Zurich and the University of St. Gallen and industry partners, including Schaer Pharma, Variosystems, and Lykke Corp.
Learn more about modum at- https://modum.io/
Follow modum ICO at – https://www.modum.io/tokensale
Access Whitepaper at – https://assets.modum.io/wp-content/uploads/2017/08/modum-whitepaper-v.-1.0.pdf
Join modum Slack channel at – http://modum.io/slack
Contact Name: Mike Taylor
Contact Email: email@example.com
Location: Zurich, Switzerland
modum.io is the source of this content. This press release is for informational purposes only and should not be viewed as an endorsement by CoinIdol. We take no responsibility and give no guarantees, warranties or representations, implied or otherwise, for the content or accuracy. Readers should do their own research before investing funds in any company.